期刊文献+

Three kinds of TNF alpha antagonists in the treatment of ankylosing spondylitis

下载PDF
导出
摘要 Objective:To study the three kinds of TNF alpha blockers treatment of ankylosing spondylitis the clinical effect, in order to select the best treatment plan, improve the level of clinical diagnosis and treatment.Method: Choose 2014-2016 in our hospital treatment of 99 cases of ankylosing spondylitis patients as the research object, the average is divided into three groups, each group of 33 cases, infliximab (Remicade, respectively adopt, in accordance with the heap, Ada wood treatment, observe the changes on the relevant index after treatment.Results: After treatment in the morning stiffness time, VAS score, BASDAI, ASDAS, blood sedimentation, c-reactive protein, MPV, propagated, PLT on indicators such as improved to some extent;On the morning stiffness time, in accordance with the heap single resistance group had the greatest reduction;ASDAS infliximab (Remicade, with single set to drop on the most obvious;VAS score and BASDAI is Ada wood sheet resistance group had the greatest reduction. On the propagated, according to the heap single resistance group had the greatest reduction;PLT, blood sedimentation, infliximab (Remicade, c-reactive protein in single resistance group had the greatest reduction;MPV is Ada wood sheet resistance group had the greatest reduction. Conclusion: The three kinds of TNF alpha antagonists' treatment of ankylosing spondylitis on clinical symptoms, signs and laboratory tests were different, each have advantages and disadvantages.
出处 《Journal of Hainan Medical University》 2018年第20期29-31,共3页 海南医学院学报(英文版)
  • 相关文献

参考文献4

二级参考文献36

  • 1边疆,郭贤坤,熊承良,黎家华,田永红,马华刚,张燕,聂勇,余伶俐,肖莉.体外rhTNF-α对人精子运动、线粒体功能影响的实验研究[J].中华男科学杂志,2004,10(6):415-419. 被引量:5
  • 2戴继灿.改良的性生活质量调查表介绍[J].中国男科学杂志,2005,19(6):71-72. 被引量:22
  • 3Pedro Martinez,Fulgencio Proverbio,Maria I. Camejo.Sperm lipid peroxidation and pro-inflammatory cytokines[J].Asian Journal of Andrology,2007,9(1):102-107. 被引量:13
  • 4Braun J 1 Sieper J. Ankylosing spondylitis [J]. Lancet, 2007, 21:1379-1390.
  • 5Kudwaleit M. New approat-hes to diagnosis anil (classification ofaxial and peripheral spondloarthrilis [J]. Curr Opin Rheumatol,2010, 22(4): 375-380.
  • 6Tong Q, Zhao DB, Bajracharya P, et al. TNF-a-857 and -1031polymorphisms predict good therapeutic response to TNF-ablockers in Chinese Han patients with ankylosing spondylitis [J].Pharmacogenomics, 2012, 13: 1459-1467.
  • 7Van der Linden S, Valkenburg HA, Cats A, et al. Evaluationof diagnostic criteria for ankylosing spondylitis: a proposal formodification of the New York criteria[J]. Arthritis Rheum, 1984,27: 361-368.
  • 8Godfrin-Valnet M,Prati C, Puyraveau M, et al. Evaluation ofspondylarthritis activity by patients and physicians: ASDAS,BASDAI, PASS, and flares in 200 patients[J]. Joint Bone Spine,2013:80: 393-398.
  • 9Lord PA, Farragher TM, Lunt M, et al. Predictors of response toanti-TNF therapy in ankylosing spondylitis : results from theBritish Society for Rheumatology Biologies Register[J], Rheuma-tology (Oxford), 2010, 49: 563-570.'.
  • 10Linares V, Alonso V, Domingo JL. Oxidative stress as a mecha-nism underlying sulfasalazine-induced toxicity [J], Expert OpinDrug Saf, 2011,1: 253-263.

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部